Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Further Reading from MarketBeat Is Abbott's January Pullback a Good Time to Buy? Author: Thomas Hughes. Date Posted: 1/24/2026. 
What You Need to Know - Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
- Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
- A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories (NYSE: ABT)'s January 2026 pullback has made the stock look attractively valued. The move appears driven more by market angst than by any real weakness — a knee-jerk overreaction that has pushed the shares back into the buy zone. 
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund.
It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you."
This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight. Click here for the full story. That zone aligns with 2022–2024 market action, when Abbott was recovering from a post–COVID-19 revenue contraction and institutions were actively accumulating the stock. Abbott Laboratories Growth Accelerates The most that can be said about Abbott Laboratories' Q4 results and guidance is that some metrics missed market expectations. Still, revenue of $11.46 billion was up 4.5% year-over-year, margins improved, and adjusted earnings accelerated. Revenue growth missed by several hundred basis points, but margin strength helped offset that — adjusted earnings per share rose about 12%, slightly above consensus. Segment-level results highlighted the strength of Abbott's diversified healthcare portfolio. Nutrition and Diagnostics contracted (Nutrition fell nearly 9%), but gains in Established Pharmaceuticals and Med Tech more than offset those declines. The pharma segment grew roughly 9%, driven by generics and emerging markets, while Med Tech increased about 12.3%, with strength across subsegments. Margin performance was encouraging even if it came in a bit shy of some analyst forecasts. A favorable product mix, strength in Med Tech, lower COVID-19 sales and operational improvements helped margins, and management expects earnings to grow another ~10% in 2026 — outpacing revenue growth and supporting the company's capital-return plans. Capital returns are central to the investment case. Abbott is a Dividend King, having raised its payout for more than 50 consecutive years, and it appears able to continue doing so. After the pullback the stock yields about 2.5%, and the payout ratio is below 50% of expected earnings, leaving room for share buybacks — an important offset to dilutive share-based compensation. Analysts Point to Robust Rebound in Abbott Laboratories Stock Some analysts flagged the revenue miss, but there were no major rating or price-target cuts the morning of the release. The prevailing view is that this is a fundamentally healthy company that can continue returning capital while reinvesting in growth, and the growth runway remains meaningful. The consensus share price target reported by MarketBeat implies potential upside of as much as 30%, which could push the stock to new all-time highs; even the low-end targets suggest some upside. Key catalysts include an expanding Med Tech portfolio, AI integration across operations and products, margin expansion and strategic acquisitions. The acquisition of Exact Sciences is one example that would broaden Abbott's revenue and profit streams as well as its product pipeline. That said, the decline in Abbott's share price has been severe and could deepen. Institutions that accumulated through 2025 are likely buyers at these discounted levels, but downside risk remains. Early technical support appears in the $105 to $110 range, though it is not yet confirmed. Shares could still drop to the low end of the target buy zone — potentially toward $95 or lower — before a sustainable rebound occurs.
| 
